Radiation sensitivity and sensitization in melanoma

Pigment Cell and Melanoma Research

Volumn 26, Issue 6, 2013, Pages 928-930

  Shahbazian, David ^a   Bindra, Ranjit S ^b   Kluger, Harriet M ^a   Glazer, Peter M ^b  

^a YALE CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL; TEMOZOLOMIDE; VEMURAFENIB;

ARTICLE; CANCER RESISTANCE; GENE MUTATION; IC 50; MELANOMA; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; SENSITIZATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; MELANOMA; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; RADIATION TOLERANCE; X-RAYS;

EID: 84886289973     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12147     Document Type: Article

References (12)

1. Carlson, B.L., Grogan, P.T., Mladek, A.C. et al. (2009). Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. Int. J. Radiat. Oncol. Biol. Phys. 75, 212-219.
2. Fertil, B., and Malaise, E.P. (1981). Inherent cellular radiosensitivity as a basic concept for human tumor radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 7, 621-629.
3. Groen, H.J., van der Leest, A.H., Fokkema, E. et al. (2004). Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study. Ann. Oncol. 15, 427-432.
4. Halaban, R., Zhang, W., Bacchiocchi, A., Cheng, E., Parisi, F., Ariyan, S., Krauthammer, M., McCusker, J.P., Kluger, Y., and Sznol, M. (2010). PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res. 23, 190-200.
5. Harwood, A.R., and Cummings, B.J. (1981). Radiotherapy for malignant melanoma: a re-appraisal. Cancer Treat. Rev. 8, 271-282.
6. Inaba, N., Kimura, M., Fujioka, K. et al. (2011). The effect of PTEN on proliferation and drug-, and radiosensitivity in malignant glioma cells. Anticancer Res. 31, 1653-1658.
7. Liebmann, J., Cook, J.A., Fisher, J., Teague, D., and Mitchell, J.B. (1994). In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J. Natl Cancer Inst. 86, 441-446.
8. Overgaard, J., Overgaard, M., Hansen, P.V., and von der Maase, H. (1986). Some factors of importance in the radiation treatment of malignant melanoma. Radiother. Oncol. 5, 183-192.
9. Sambade, M.J., Peters, E.C., Thomas, N.E., Kaufmann, W.K., Kimple, R.J., and Shields, J.M. (2011). Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother. Oncol. 98, 394-399.
10. Stevens, G., and McKay, M.J. (2006). Dispelling the myths surrounding radiotherapy for treatment of cutaneous melanoma. Lancet Oncol. 7, 575-583.
11. Wedge, S.R., Porteous, J.K., Glaser, M.G., Marcus, K., and Newlands, E.S. (1997). In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs 8, 92-97.
12. Yang, L.X., Douple, E.B., O'Hara, J.A., and Wang, H.J. (1995). Production of DNA double-strand breaks by interactions between carboplatin and radiation: a potential mechanism for radiopotentiation. Radiat. Res. 143, 309-315.